Published in Science on January 16, 1987
AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol (1988) 1.39
SIV infection in natural hosts: resolution of immune activation during the acute-to-chronic transition phase. Microbes Infect (2010) 0.95
Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol (1990) 0.82
Inflammatory joint disease and HIV infection. BMJ (1988) 0.75
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ (1999) 2.44
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. Arch Intern Med (1996) 2.33
In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother (1998) 2.32
Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun (1985) 2.25
Neopterin as a marker for immune system activation. Curr Drug Metab (2002) 2.25
Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A (1975) 2.21
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett (1991) 1.96
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem (2001) 1.95
Immune activation and psoriasis. Lancet (1991) 1.93
Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol Cell Biol (1996) 1.86
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis (1998) 1.77
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med (1991) 1.71
Gas gangrene: necropsy is imperative. Lancet (1996) 1.69
Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem (1989) 1.66
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (2001) 1.63
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J (1993) 1.61
The pteridine binding site of brain nitric oxide synthase. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain. J Biol Chem (1994) 1.61
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem (1989) 1.59
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med (1994) 1.55
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
[Vancomycin resistant enterococci in Austria]. Wien Klin Wochenschr (1997) 1.51
Systematic study of four years of internship. Pediatrics (1980) 1.51
An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med (2000) 1.51
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother (2001) 1.50
Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine (1992) 1.47
Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47
Acquisition of host cell-surface-derived molecules by HIV-1. AIDS (1996) 1.46
Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol (1996) 1.45
Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. J Biol Chem (1996) 1.45
Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Eur J Immunol (1990) 1.44
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci (1992) 1.42
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
[Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases (author's transl)]. Hoppe Seylers Z Physiol Chem (1979) 1.41
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab (2002) 1.40
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
Evaluation of the adaptive learning environments model. Except Child (1988) 1.40
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr (1990) 1.39